Chinook Therapeutics, Inc.
Chinook Therapeutics (Nasdaq: KDNY) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. Chinook has locations in Vancouver, BC, Seattle, WA and Oakland, CA. To learn more, visit www.chinooktx.com.
- website: http://www.chinooktx.com
- twitter: https://twitter.com/ChinookTx
- linkedin: http://www.linkedin.com/company/chinook-therapeutics-inc
- angellist: http://angel.co/aduro-biotech